Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma

Gun Ick Hwang; Chang Hak Yoo; Byung Ho Sohn; Jun Ho Shin; Yong Lai Park; Heung Dai Kim; Yong Shin Kim; Won Kon Han; Won Kil Pae

doi:10.4143/crt.2004.36.3.178

Articles

Page Path: HOME > Cancer Res Treat > Volume 36(3); 2004 > Article

Original Article Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma: Gun Ick Hwang, M.D., Chang Hak Yoo, M.D., Byung Ho Sohn, M.D., Jun Ho Shin, M.D., Yong Lai Park, M.D., Heung Dai Kim, M.D., Yong Shin Kim, M.D., Won Kon Han, M.D., Won Kil Pae, M.D.; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2004;36(3):178-181.
DOI: https://doi.org/10.4143/crt.2004.36.3.178
Published online: June 30, 2004

Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence: Chang Hak Yoo, Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 108 Pyeong-dong, Jongno-gu, Seoul 110-102, Korea. (Tel) 82- 2-2001-2460, (Fax) 82-2-2001-2131, chyoo63@naver.com

• Received: April 8, 2004 • Accepted: May 18, 2004

11,381 Views
78 Download
40 Crossref

prev next

Full Article

Download PDF

Abstract

Purpose
Peritoneal metastasis is a crucial factor for the prognosis in gastric cancer, but its diagnosis is difficult before laparotomy. This study analyzed the usefulness of diagnostic imaging and various tumor markers in the detection of peritoneal metastasis in gastric cancer.
Materials and Methods
The sera from 768 patients with gastric cancer were measured for CEA, CA19-9 and CA125 levels using a commercial immunoradiometric assay. All the patients underwent diagnostic imaging with computed tomography (CT) and ultrasound (US) before laparotomy.
Results
Preoperative levels of CEA, CA19-9 and CA125 were above the cut-off levels in 15.4%, 8.7% and 5.7% of all cases, respectively. Eighty-eight patients were diagnosed with peritoneal metastasis by laparotomy. CT and US revealed peritoneal dissemination in 15 of 88 patients (17%). Among the three tumor markers, CA19-9 and CA125 showed similar detection rates of peritoneal metastasis (37.5% and 38.6%, respectively). In particular, the serum CA125 levels showed the best sensitivity (38.6%), specificity (98.4%), and diagnostic accuracy (91.5%), and the highest odd ratio (24.46, 95% CI: 11.17~53.57) for predicting peritoneal metastasis among the markers tested. CEA did not add significant predictive information (p=0.471).
Conclusion
Preoperative serum CA19-9 and CA125 levels may provide a predictable value in determining peritoneal metastasis in patients with gastric cancer.
Key words: Stomach neoplasm, CEA, CA19-9, CA125, Peritoneal metastasis

INTRODUCTION

The prognosis for gastric cancer with peritoneal metastasis is very dismal, and the quality of life quickly deteriorates because of symptoms such as massive ascites, ileus, and cachexia. Since any delay in diagnosis is detrimental for patients with peritoneal metastasis, it is important to diagnose the degree and extent of peritoneal metastasis, and to make prompt decisions about applicable treatments. Unfortunately, however, the currently used diagnostic imaging techniques such as computed tomography (CT), and ultrasonography (US) often fail to provide an accurate prediction of peritoneal metastasis.

Many papers have been published on the relationship between peritoneal metastasis and different markers such as cytology findings (1), tumor markers (2,3), and molecular markers (4). Although there are no specific tumor-associated antigens in gastric cancers, carcinoembryonic antigen (CEA) and carbohydrate antigens of the sialyl-Lewis A group, such as CA19-9, are known to be elevated in the serum of patients with advanced gastric cancer (5~7). Besides, another carbohydrate antigen, CA125, was also mentioned in the literature. CA125 represents a protein normally expressed by cells lining the fallopian tubes, endometrium, endocervix, peritoneum, pleura and pericardium (8). Serum CA125 is a tumor marker extensively used in patients with ovarian cancer (9).

In this prospective study, we measured preoperative serum CEA, CA19-9, and CA125 levels in patients with gastric cancer and then evaluated the predictive values of these tumor markers for peritoneal metastasis from gastric cancer.

PATIENTS AND METHODS

Seven hundred and sixty-eight patients with histologically proven gastric carcinoma who underwent surgery between July 1999 and December 2003 were enrolled in this study. There were 534 males and 234 females. The mean age±standard deviation was 57.3±11.9 years (range 20~83 years). Of these 768 patients, total gastrectomy was performed in 128 patients (16.7%), subtotal gastrectomy in 538 patients (70.0%), proximal gastrectomy in 37 patients (4.8%), and explo-laparotomy or by-pass procedures in 65 patients (8.5%). According to the Union Internationale Contra le Cancer (UICC) TNM classification (10), 351 patients had Stage I disease, 111 had Stage II disease, 154 had Stage III disease, and 152 had Stage IV disease.

All the patients underwent diagnostic imaging by CT and US before laparotomy. Ascites, Krukenberg tumor, and/or omental cake were regarded as peritoneal metastasis. The degree of peritoneal metastasis was defined according to the criteria of the Japanese Research Society for Gastric Cancer (11): P1, metastases to the adjacent peritoneum but not distant peritoneum; P2, a few metastases to the distant peritoneum; P3, numerous metastases to the distant peritoneum.

Peripheral blood samples were obtained from each patient within 1 week before surgery. The commercial immunoradiometric assay was used for measurement of CEA (CIS bio international, Yvette, France), CA19-9 (Immunotech, Marseille, France), and CA125 (Fujirebio Diagnostics, PA, USA).

The cutoff values for serum CEA, CA19-9, and CA125 were 5 ng/ml, 37 U/ml, and 35 U/ml, respectively, according to the manufacturer's instructions.

The nonparametric Mann-Whitney U test was used for comparison of the two independent groups. The predictive value of each tumor marker was assessed by a logistic regression model. A p value less than 0.05 was considered to be statistically significant. All statistical analyses were carried out with the Statistical Package for the Social Science (SPSS, Chicago, IL) program.

RESULTS

Preoperative levels of CEA, CA19-9 and CA125 were above the cut-off levels in 15.4%, 8.7% and 5.7% of all cases, respectively. Eighty-eight patients were diagnosed with peritoneal metastasis by laparotomy. The diagnostic abilities of various examinations for peritoneal metastasis are summarized in Table 1. Diagnostic imaging (CT and US) revealed peritoneal dissemination in 15 of 88 patients (17%) and showed the lowest sensitivity among these examinations. Among the three tumor markers, CA19-9 and CA125 showed similar detection rates of peritoneal metastasis (37.5% and 38.6%, respectively). As the degree of peritoneal dissemination increased, the positive rate of CA125 increased, whereas the positive rate of CEA decreased accordingly.

As shown in Table 2, almost the same trend was observed for the correlations between the mean±SD values of serum CEA, CA19-9, and CA125 and the degree of peritoneal dissemination. The serum CA125 levels were significantly higher in P1 through P3 than in P0. However, P1 tumor showed a higher CEA level than did P2 through P3 tumors.

Fig. 1 shows a comparison of various tumor markers for peritoneal metastasis. For CEA, CA19-9 and CA125, each cut-off value was used as a reference value for peritoneal metastasis. CA125 had the best sensitivity (38.6%), specificity (98.4%), and accuracy (91.5%). CA19-9 had the second best sensitivity (37.5%), specificity (95%), and accuracy (88.4%). In contrast, CEA had the worst sensitivity (31.8%), specificity (86.7%), and accuracy (80.4%) among these tumor markers.

The multivariate analysis indicated that patients with preoperative serum CA125 above 35 U/ml had the highest odd ratio (24.46, 95% CI: 11.17~53.57) for predicting peritoneal metastasis among the markers tested. CEA did not add significant predictive information (p=0.471) (Table 3).

DISCUSSION

Peritoneal metastasis is one of the most difficult problems in patients with gastric carcinoma in terms of diagnosis and treatment. Diagnosis for the peritoneal metastasis involves recognition of ascites on physical examination, recognition of induration of the pouch of Douglas by digital examination, or the use of diagnostic imaging techniques such as CT, US, or magnetic resonance imaging (MRI). However, none of these methods has demonstrated a high predictive value. Therefore, until now, laparotomy plays an important role in the diagnosis of peritoneal metastasis by the direct observation of peritoneal cavity and the estimation of resectability.

Our data indicated a poor sensitivity of CT/US for detecting the peritoneal metastasis. Even for patients with numerous metastases to the distant peritoneum (P3), the diagnostic ability of these examinations was only 37.5%, and these results are comparable to those of other studies (2,12). Recently, laparoscopic examination has been reported to be useful in the detection of peritoneal metastasis (12,13). It allows the direct inspection of the peritoneal cavity, biopsy of suspect nodules, and cytological investigation of washings. It also affords an opportunity to identify small omental and peritoneal implants which may not be detected by imaging modalities. However, its use is not yet prevalent in clinical practice. Surgeons might hesitate to perform laparoscopy before surgical treatment because it is still invasive, although less so than open laparotomy, and is time-consuming and costly.

Many tumor markers, such as CEA, CA19-9, CA72-4, CA125, and CA50, have been studied in the monitoring of gastric cancer, but the sensitivity of any one of them is not sufficient (14~16). CEA and CA19-9 are probably the most well-investigated of all markers to date, and serial examinations have been found useful in postoperative follow-up and detection of recurrence in patients with gastric cancer. CA125 is a sensitive, but not specific, tumor marker that is especially used in the diagnosis and follow-up of ovarian cancer. Lung, liver, biliary tract, stomach, colorectal, and pancreatic malignant tumors are all associated with an increase of serum CA125 levels. This marker is also increased in patients with heart failure, benign pleuropulmonary diseases, peritoneal tuberculosis, and liver cirrhosis. The probable etiology of this marker increment is a diffuse insult to the mesothelial cells. When mesothelial cells of the pleura, peritoneum, pericardium, or fallopian tube are abnormally stimulated, they can increase their normal production of CA125, and its serum level increases (17,18). Only few studies have addressed the possible value of these tumor markers as a preoperative monitor of peritoneal dissemination (2,12).

Our study showed that preoperative positivities for CEA, CA19-9 and CA125 were 15.4%, 8.7% and 5.7%, respectively, in all 768 patients with gastric cancer. However, the sensitivities for peritoneal metastasis were 31.8%, 37.5%, and 38.6%, respectively, in 88 patients with peritoneal metastasis. These significant increases in sensitivity suggested that the serum levels of CA25 and CA19-9 would be highly suitable for monitoring for peritoneal metastasis. Moreover, patients with high CA125 and CA19-9 showed 24.26-fold and 6.27-fold risk of peritoneal metastasis as compared to those with low levels, respectively, at the multivariate analysis (p<0.001). Our study also disclosed that serum CA125 levels were significantly higher in P1 through P3 than in P0; this may reflect the peritoneal dissemination may cause inflammation of peritoneum. On the contrary, we found that P1 tumor showed a higher CEA level than did P2 through P3 tumors. This finding suggested a strong correlation between the serum CEA level and other organ involvement of tumor, such as lymph node or liver, rather than peritoneal involvement.

However, the positivity rate of CA125 in our patients with gastric cancer was quite low (5.7%). We do not propose CA125 as a convenient marker for gastric cancer; it may be useful in patients with highly suspicious peritoneal metastasis prior to surgery or chemotherapy.

CONCLUSIONS

Preoperative serum CA19-9 and CA125 levels may provide a predictable value in determining peritoneal metastasis in patients with gastric cancer. In particular, the serum CA125 levels have the best sensitivity, specificity, and diagnostic accuracy, and the highest odd ratio for predicting peritoneal metastasis among the various examinations. Therefore, surgeons can be better prepared for alternative therapy, such as diagnostic laparoscopy or intraperitoneal chemotherapy.

REFERENCES

1. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G, Miwa K. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178:256–262. PMID: 10527450Article PubMed
2. Nakata B, Hirakawa K, Kato Y, Yamashita Y, Maeda K, Onoda N, Sawada T, Sowa M. Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 1998;83:2488–2500. PMID: 9874453Article PubMed
3. Nishiyama M, Takashima I, Tanaka T, Yoshida K, Toge T, Nagata N, Iwamori S, Tamura Y. Carcinoembryonic antigen levels in the peritoneal cavity: useful guide to peritoneal recurrence and prognosis for gastric cancer. World J Surg. 1995;19:133–137. PMID: 7740800Article PubMed
4. Fujimura T, Ohta T, Kitagawa H, Fushida S, Nishimura GI, Yonemura Y, Elnemr A, Miwa K, Nakamura Y. Trypsinogen expression and early detection for peritoneal dissemination in gastric cancer. J Surg Oncol. 1998;69:71–75. PMID: 9808508Article PubMed
5. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol. 1996;91:49–53. PMID: 8561143PubMed
6. Yook JH, Kim BS, Kim YH, Suh BS, Kim WS, Oh ST, Park KC. Diagnostic value of tumor markers in stomach cancer. J Korean Cancer Assoc. 1999;31:1094–1100.
7. Baek SW, Cho DH, Yoo CH, Han WK. Prognostic value of preoperative serum CEA and CA19-9 levels in gastric cancer patients. J Korean Surg Soc. 2004;66:27–32.
8. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–285. PMID: 6196309Article PubMed
9. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer. 1984;50:765–769. PMID: 6208925Article PubMed PMC
10. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 1997. 5th ed. New York: Wiley-Liss.
11. Japanese Research Society for Gastric CancerJapanese classification of gastric carcinoma. 1998. 2nd English ed. Tokyo: Kanehara.
12. Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, Kayahara M, Shimizu K, Ohta T, Miwa K. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy. 2002;34:569–574. PMID: 12170412Article PubMed
13. D'Ugo DM, Persiani R, Caracciolo F. Selection of locally advanced gastric carcinoma by preoperative staging laparoscopy. Surg Endosc. 1997;11:1159–1162. PMID: 9373285Article PubMed
14. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazoto H. The usefulness of CEA and/or Ca19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142–145. PMID: 14520526Article PubMed
15. Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterol. 2002;49:1157–1160.
16. Gaspar MJ, Arribas I, Coca MC, Alonso MD. Prognostic value of carcinoembryonic antigen, CA19-9 and CA72-4 in gastric carcinoma. Tumor Biol. 2001;22:318–322. Article
17. Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos B, Cubedo R, Carcereny E, Bonilia F, Gea T. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10:150–154. PMID: 12620910Article PubMed
18. Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA125 levels in patients with serosal involvement? A clinical dilemma. Oncology. 2003;65:1–6. PMID: 12837976Article

Fig. 1

Comparison of diagnostic ability of peritoneal metastasis by each tumor marker. Solid bar: sensitivity; open bar: specificity; shaded bar: diagnostic accuracy. Sensitivity=(patients with peritoneal metastasis with positive tests/all patients with peritoneal metastasis tested) ×100; Specificity=(patients without peritoneal metastasis with negative tests/all patients without peritoneal metastasis tested) ×100; Diagnostic accuracy=(patients with peritoneal metastasis with positive tests+patients without peritoneal metastasis with negative tests)/(all patients tested) ×100.

Table 1

Comparison of diagnostic abilities of imaging studies (CT and US) and tumor markers for peritoneal metastasis from gastric cancer

Table 2

The mean±SD values of serum CEA, CA19-9 and CA125 for patients without and with peritoneal metastases

^*p<0.001 by the Mann-Whitney U test.

Table 3

Comparison of the diagnostic ability of serum tumor marker levels for peritoneal metastasis

^*95% confidence interval.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer
Chuhong Pang, Yubo Ma, Wenyi Shi, Mengli Zi, Jinxia Chen, Chen Liang, Xiao Li, Zhuo Liu, Yian Du
Journal of Gastrointestinal Surgery.2024; 28(5): 694. CrossRef
Development of Panel of Three-Dimensional Biomarkers to Identify Gastric Carcinoma and Precancerous Lesions of the Stomach - An Analytical Cross-Sectional Study
Sandhya Karra, Ramanan Sinduja, Balakrishnan Gurushankari, T. P. Elamurugan, Thulasingam Mahalakshmy, Vikram Kate, Nivedita Nanda, Nachiappa Ganesh Rajesh, Murugesan Rajeswari, Ruben Raj, Gomathi Shankar
Indian Journal of Clinical Biochemistry.2024;[Epub] CrossRef
Usefulness of Diagnostic Staging Laparoscopy for Advanced Gastric Cancer
Kozo Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto
The American Surgeon™.2023; 89(4): 685. CrossRef
Intraoperative Pathological Evaluation of Suspicious Peritoneal Nodules for Surgical Decision-making in Gastric Cancer
Chen Wang, Junjie Zhao, Jie Sun, Chenyu Tian, Zhiqiang Dai, Jingdong Liu, Chengbo Ji, Dan Liu, Xuefei Wang, Haojie Li, Yihong Sun
Journal of Gastrointestinal Surgery.2023; 27(8): 1545. CrossRef
Development and validation of a CT radiomics and clinical feature model to predict omental metastases for locally advanced gastric cancer
Ahao Wu, Changlei Wu, Qingwen Zeng, Yi Cao, Xufeng Shu, Lianghua Luo, Zongfeng Feng, Yi Tu, Zhigang Jie, Yanyan Zhu, Fuqing Zhou, Ya Huang, Zhengrong Li
Scientific Reports.2023;[Epub] CrossRef
Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors
Qi Wang, Qiang Zhang, Jiankang Zhu, Linchuan Li, Runzhi Zeng, Huanxin Ding, Zhenmin Li, Tianyi Feng, Ruiqi Hao, Guangyong Zhang
Clinical and Translational Oncology.2023; 26(4): 1001. CrossRef
Does CA 125 Predict Peritoneal Dissemination in Patients with Gastric Cancer?
Murat Güner, Tayfun Kaya, Cengiz Aydın
Indian Journal of Surgery.2022; 84(4): 779. CrossRef
Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer
Jiang Huang, Yidi Chen, Yuying Zhang, Jinhuan Xie, Yiqiong Liang, Wenzhao Yuan, Ting Zhou, Ruizhi Gao, Rong Wen, Yuwei Xia, Liling Long
Abdominal Radiology.2022; 47(1): 66. CrossRef
Clinical effect of 64-row spiral CT combined with multiple tumor markers in the diagnosis of gastric cancer and its effect on accuracy
Libo YU, Lei LI, Meiying YU, Jun CHEN
Minerva Medica.2022;[Epub] CrossRef
Investigation of serum markers of esophageal squamous cell carcinoma based on machine learning methods
Zhifeng Ma, Ting Zhu, Haiyong Wang, Bin Wang, Linhai Fu, Guangmao Yu
The Journal of Biochemistry.2022; 172(1): 29. CrossRef
Construction of a Nomogram Model for Predicting Peritoneal Dissemination in Gastric Cancer Based on Clinicopathologic Features and Preoperative Serum Tumor Markers
Dandan Bao, Zhangwei Yang, Senrui Chen, Keqin Li, Yiren Hu
Frontiers in Oncology.2022;[Epub] CrossRef
Novel CT based clinical nomogram comparable to radiomics model for identification of occult peritoneal metastasis in advanced gastric cancer
Lili Wang, Peng Lv, Zhen Xue, Lihong Chen, Bin Zheng, Guifang Lin, Weiwen Lin, Jingming Chen, Jiangao Xie, Qing Duan, Jun Lu
European Journal of Surgical Oncology.2022; 48(10): 2166. CrossRef
Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy
Zhemin Li, Guangmin Guan, Zining Liu, Jiazheng Li, Xiangji Ying, Fei Shan, Ziyu Li
Frontiers in Surgery.2022;[Epub] CrossRef
Collagen Family as Promising Biomarkers and Therapeutic Targets in Cancer
Laura Necula, Lilia Matei, Denisa Dragu, Ioana Pitica, Ana Neagu, Coralia Bleotu, Carmen C. Diaconu, Mihaela Chivu-Economescu
International Journal of Molecular Sciences.2022; 23(20): 12415. CrossRef
Risk factors associated with peritoneal carcinomatosis of gastric cancer in staging laparoscopy: A systematic review and meta-analysis
Guangmin Guan, Zhemin Li, Qi Wang, Xiangji Ying, Fei Shan, Ziyu Li
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Applications of Liquid Biopsy in Gastric Cancer
Mihaela Chivu-Economescu, Laura Necula, Lilia Matei, Denisa Dragu, Coralia Bleotu, Carmen C. Diaconu
Frontiers in Medicine.2021;[Epub] CrossRef
A Novel Nomogram Integrated with Inflammation-Based Factors to Predict the Prognosis of Gastric Cancer Patients
Xueping Wang, Minjie Mao, Shihao Zhu, Shan Xing, Yiling Song, Lin Zhang, Peidong Chi
Advances in Therapy.2020; 37(6): 2902. CrossRef
Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma

Yao Huang, Jianxing Zeng, Teng Liu, Xinju Lin, Pengfei Guo, Jinhua Zeng, Weiping Zhou, Jingfeng Liu
OncoTargets and Therapy.2020; Volume 13: 4559. CrossRef
Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers
Yanyan Chen, Quan Zhou, Haiyong Wang, Wei Zhuo, Yongfeng Ding, Jun Lu, Guanghao Wu, Nong Xu, Lisong Teng
Cancers.2020; 12(8): 2236. CrossRef
A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer
Junjie Zhao, Ruihuan Qin, Hao Chen, Yupeng Yang, Wenjun Qin, Jing Han, Xuefei Wang, Shifang Ren, Yihong Sun, Jianxin Gu
Clinical Proteomics.2020;[Epub] CrossRef
Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading
Bayazid Ghaderi, Hamoon Moghbel, Nasrin Daneshkhah, Asrin Babahajian, Farshad Sheikhesmaeili
Journal of Gastrointestinal Cancer.2019; 50(3): 525. CrossRef
Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers
Caleb Harris, Vikas Ostwal, Dilip Harindran Vallathol, Rohit Dusane, Sarika Mandavkar, Shraddha Patkar, Anant Ramaswamy, Shailesh V. Shrikhande
South Asian Journal of Cancer.2019; 08(03): 166. CrossRef
Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination
Chao Huang, Zitao Liu, Li Xiao, Yongqiang Xia, Jun Huang, Hongliang Luo, Zhen Zong, Zhengming Zhu
Frontiers in Oncology.2019;[Epub] CrossRef
A new score for screening of malnutrition in patients with inoperable gastric adenocarcinoma
Ali Esfahani, Mohammad Hossein Somi, Mohammad Asghari Jafarabadi, Alireza Ostadrahimi, Mousa Ghayour Nahand, Zahra Fathifar, Akram Doostzadeh, Zohreh Ghoreishi
Japanese Journal of Clinical Oncology.2017; 47(6): 475. CrossRef
Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer
Xiao-dong Chen, Chen-chen Mao, Rui-sen Wu, Wei-teng Zhang, Ji Lin, Xiang-wei Sun, Chu-huai Chi, Neng Lou, Peng-fei Wang, Xian Shen, Guan-bao Zhu, Shu-rong Shen, Valli De Re
PLOS ONE.2017; 12(4): e0175074. CrossRef
Tumor volume increases the predictive accuracy of prognosis for gastric cancer: A retrospective cohort study of 3409 patients
Zhen Liu, Peng Gao, Shushang Liu, Gaozan Zheng, Jianjun Yang, Li Sun, Liu Hong, Daiming Fan, Hongwei Zhang, Fan Feng
Oncotarget.2017; 8(12): 18968. CrossRef
Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases
Fan Wu, Chunmei Shi, Riping Wu, Zhiqing Huang, Qiang Chen
Oncotarget.2017; 8(44): 78120. CrossRef
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options
Nina Sluiter, Erienne de Cuba, Riom Kwakman, Geert Kazemier, Gerrit Meijer, Elisabeth Atie te Velde
Clinical & Experimental Metastasis.2016; 33(5): 401. CrossRef
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
LIANG LIU, JINFENG XIANG, RUFU CHEN, DELIANG FU, DEFEI HONG, JIHUI HAO, YIXIONG LI, JIANGTAO LI, SHENGPING LI, YIPING MOU, GANG MAI, QUANXING NI, LI PENG, RENYI QIN, HONGGANG QIAN, CHENGHAO SHAO, BEI SUN, YONGWEI SUN, MIN TAO, BOLE TIAN, HONGXIA WANG, JIA
International Journal of Oncology.2016; 48(3): 900. CrossRef
Clinical Significance of CA125 Level with Clinicopathological Variables and Peritoneal Dissemination in Patients with Gastric Carcinoma
Laila Shirin
Gastroenterology & Hepatology: Open Access.2016;[Epub] CrossRef
Prognostic values of normal preoperative serum cancer markers for gastric cancer
Fan Feng, Li Sun, Zhen Liu, Shushang Liu, Gaozan Zheng, Guanghui Xu, Man Guo, Xiao Lian, Daiming Fan, Hongwei Zhang
Oncotarget.2016; 7(36): 58459. CrossRef
Marqueurs sériques
M. Vallée, D. Tougeron
EMC - Gastro-entérologie.2016; 33(4): 1. CrossRef
Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients
Dae Hoon Kim
World Journal of Gastroenterology.2015; 21(4): 1216. CrossRef
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association
Hideaki Shimada, Tamaki Noie, Manabu Ohashi, Koji Oba, Yutaka Takahashi
Gastric Cancer.2014; 17(1): 26. CrossRef
Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer
Hao Lai, Qinwen Jin, Yuan Lin, Xianwei Mo, Bo Li, Ke He, Jiansi Chen
Tumor Biology.2014; 35(10): 10547. CrossRef
Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer
Shu-Bo Tian, Jian-Chun Yu, Wei-Ming Kang, Zhi-Qiang Ma, Xin Ye, Zhan-Jiang Cao, Chao Yan
Asian Pacific Journal of Cancer Prevention.2014; 15(15): 6295. CrossRef
Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination
Shigenobu Emoto, Hironori Ishigami, Hiroharu Yamashita, Hironori Yamaguchi, Shoichi Kaisaki, Joji Kitayama
Gastric Cancer.2012; 15(2): 154. CrossRef
Pilot Feasibility Study of Neoadjuvant Chemoradiotherapy with S-1 in Patients with Locally Advanced Gastric Cancer Featuring Adjacent Tissue Invasion or JGCA Bulky N2 Lymph Node Metastases
Tatsushi Inoue, Shinichi Yachida, Hisashi Usuki, Tomoki Kimura, Masanobu Hagiike, Keiichi Okano, Yasuyuki Suzuki
Annals of Surgical Oncology.2012; 19(9): 2937. CrossRef
Serum levels of CA19-9 may be as an indicator for metastases in patients with non-small cell lung cancer
Xing’an Liu, Guoyong Shan, Song Zhang, Kaijian Lei
The Chinese-German Journal of Clinical Oncology.2011; 10(12): 692. CrossRef
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
HanByoul Cho, Hye Won Hur, Sang Wun Kim, Sung Hoon Kim, Jae Hoon Kim, Young Tae Kim, Kook Lee
Cancer Immunology, Immunotherapy.2009; 58(1): 15. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma

Cancer Res Treat. 2004;36(3):178-181. Published online June 30, 2004

DOI: https://doi.org/10.4143/crt.2004.36.3.178

XML Download

Abstract
INTRODUCTION
PATIENTS AND METHODS
RESULTS
DISCUSSION
CONCLUSIONS
REFERENCES

Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma

Fig. 1 Comparison of diagnostic ability of peritoneal metastasis by each tumor marker. Solid bar: sensitivity; open bar: specificity; shaded bar: diagnostic accuracy. Sensitivity=(patients with peritoneal metastasis with positive tests/all patients with peritoneal metastasis tested) ×100; Specificity=(patients without peritoneal metastasis with negative tests/all patients without peritoneal metastasis tested) ×100; Diagnostic accuracy=(patients with peritoneal metastasis with positive tests+patients without peritoneal metastasis with negative tests)/(all patients tested) ×100.

Fig. 1

Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma

Table 1

Comparison of diagnostic abilities of imaging studies (CT and US) and tumor markers for peritoneal metastasis from gastric cancer

Table 2

The mean±SD values of serum CEA, CA19-9 and CA125 for patients without and with peritoneal metastases

^*p<0.001 by the Mann-Whitney U test.

Table 3

Comparison of the diagnostic ability of serum tumor marker levels for peritoneal metastasis

^*95% confidence interval.

Table 1 Comparison of diagnostic abilities of imaging studies (CT and US) and tumor markers for peritoneal metastasis from gastric cancer

Table 2 The mean±SD values of serum CEA, CA19-9 and CA125 for patients without and with peritoneal metastases

^*p<0.001 by the Mann-Whitney U test.

Table 3 Comparison of the diagnostic ability of serum tumor marker levels for peritoneal metastasis

^*95% confidence interval.